In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover Risk-free dosing program. Extra members will be enrolled with the discovered monotherapy dosign program. In Segment B, participants will obtain oral ruxolitinib and ABBV-744 might be presented as "increase-on" therapy. In Segment C, participants https://abbv-744cancertreatmentcl91346.ttblogs.com/11647139/top-brd4-inhibition-by-abbv-744-in-cancer-research-studies-secrets